Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
Our analysis suggests that toripalimab plus chemotherapy is likely to be a cost-effective first-line therapy for ES-SCLC compared to chemotherapy alone, based on the WTP threshold of $40343.68 per QALY.
Authors
- Huide Zhu
- Hongcai Chen (ORCID: https://orcid.org/0000-0001-5418-4122)
- Zhiwei Zheng (ORCID: https://orcid.org/0000-0002-7815-3221)
- Longfeng Zhang
Institutions
- Fujian Medical University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1591517
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05